Navigation Links
XTENT Announces Second Quarter 2008 Financial Results and Business Progress
Date:8/6/2008

MENLO PARK, Calif., Aug. 6 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT) today reported financial results for the second quarter and six months ended June 30, 2008 and provided an update on its business.

The company reported a net loss of $12.9 million, or $0.56 per share, for the second quarter of 2008, compared to a net loss of $9.5 million, or $0.42 per share, for the second quarter of 2007. The company's net loss for the second quarter of 2008 was based on weighted average shares outstanding of 23.0 million as compared to 22.6 million weighted average shares outstanding for the second quarter of 2007. For the six months ended June 30, 2008, XTENT had a net loss of $25.3 million, compared to $17.4 million for the same period last year. As of June 30, 2008, XTENT had cash, cash equivalents and short-term investments of $34.4 million.

Research and development expenses increased to $9.8 million in the second quarter of 2008 from $7.7 million for the same period in 2007, primarily due to an increased number of research and development personnel, expenditures for prototype parts and supplies as well as costs incurred for clinical trials. General and administrative expenses were $3.3 million in the second quarter of 2008 versus $2.8 million for the same period in 2007, primarily due to an increase in personnel costs related to the hiring of additional employees as well as consulting, legal, professional services and other administrative costs associated with operating as a public company. Research and development expenses for the six month period ended June 30, 2008 totaled $19.2 million, compared to $13.9 million for the same period last year. General and administrative expenses for the six months ended June 30, 2008 totaled $6.8 million compared to $5.3 million for the same period in 2007.

On July 9, 2008, XTENT announced the implementation of cost reduction initiatives through a workforce reduction of approximately 34 percent. The company expects to incur approximately $300,000 to $400,000 in expenses in connection with this workforce reduction including approximately $100,000 of non-cash expenses. Most of the expenses will be incurred during the third quarter of 2008. Average cost savings from the workforce reduction initiative, combined with other cost saving initiatives planned by the company, is anticipated to be approximately $1.3 million each month.

"We recently conducted a review of our business and made the difficult decision of reducing headcount in order to ensure that we remain in a strong position to bring our Custom NX(R) drug eluting stent (DES) system to the millions of patients worldwide who suffer from coronary artery disease," said Gregory D. Casciaro, XTENT's President and Chief Executive Officer. "We continue to be pleased with the safety profile and efficacy data of Custom NX in today's real-world patients, and look forward to providing additional long term follow up data at the upcoming Transcatheter Cardiovascular Therapeutics meeting in October."

Second Quarter 2008 Highlights

-- Presented positive CUSTOM III six-month follow-up data during the Late Breaking Trials Session at EuroPCR.

-- Received EuroIntervention award for CUSTOM I two-year results at EuroPCR.

Regulatory Update

XTENT also announced that it recently received a response from the Medicine Evaluations Board (MEB) through its designated European Notified Body regarding its CE Mark application for Custom NX. The MEB has indicated that it may require additional clinical data, including a randomized trial. The company is working with the Notified Body to respond to questions included in the MEB's letter and expects to meet with a panel from the MEB during the fourth quarter of this year.

"We expected to receive questions from the MEB which we believe is typical of most initial submissions," commented Casciaro. "We are working expeditiously to respond to their questions. The opportunity for Custom NX in select non-U.S. markets, including Europe and Asia-Pacific, remains significant and attractive, and we are exploring strategic options related to the distribution of Custom NX in these markets."

Casciaro added, "In the U.S., we are engaged in ongoing discussions with the Food and Drug Administration (FDA) in order to obtain approval of our application for an investigational device exemption (IDE) to commence pivotal trials. We have established an agreed upon timeline of deliverables and, while we believe we are on track to receive approval of our IDE application before the end of 2008, we now expect to commence our pivotal trials in 2009."

About XTENT

XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device. Note: XTENT(R) Custom NX(R) DES Systems have not been approved for sale by any regulatory authority.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding XTENT's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Specifically, these statements include, but are not limited to those concerning: XTENT's expectations with respect to the timing of its regulatory filings, the timing of regulatory approvals, the timing of the commercialization of its products, the timing of the initiation of its U.S. clinical trial, and the timing and amount of any savings that may result from the company's cost reduction initiatives. Forward-looking statements are based on management's current, preliminary expectations, and are subject to risks and uncertainties that could cause actual results to differ from the results predicted and which are included in the "Risk Factors" section of XTENT's most recent quarterly report on Form 10-Q for the quarter ended March 31, 2008. This quarterly report was filed with the SEC on May 13, 2008, and is available on the company's investor relations website at http://www.xtentinc.com and on the SEC's website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. XTENT undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

XTENT, INC.

(a development stage company)

Condensed Statements of Operations

(unaudited; in thousands, except per share amounts)

Three Months Ended Six Months Ended

June 30, June 30,

2008 2007 2008 2007

Operating expenses:

Research and development (1) $9,818 $7,704 $19,239 $13,927

General and administrative (1) 3,331 2,801 6,773 5,262

Total operating expenses 13,149 10,505 26,012 19,189

Loss from operations (13,149) (10,505) (26,012) (19,189)

Interest and other income, net 263 1,049 669 1,798

Net loss $(12,886) $(9,456) $(25,343) $(17,391)

Net loss per share - basic and

diluted $(0.56) $(0.42) $(1.10) $(0.93)

Weighted-average common shares

outstanding used in per share

calculation 23,033 22,551 22,978 18,649

(1) Includes the following stock-based compensation charges:

Research and development $393 $348 $781 $736

General and administrative $695 $413 $1,345 $832

XTENT, INC.

(a development stage company)

Condensed Balance Sheets

(unaudited, in thousands)

June 30, 2008 December 31, 2007

Cash, cash equivalents and short term

investments $34,427 $57,760

Working capital 31,355 54,581

Total assets 39,507 62,415

Deficit accumulated during the

development stage (118,203) (92,860)

Total stockholders' equity 35,345 58,331


'/>"/>
SOURCE XTENT, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. XTENT Appoints Christopher M. Smith and Arthur T. Taylor to Board of Directors
2. XTENT Announces CUSTOM I Data Receives Recognition from EuroIntervention
3. XTENT to Present at Cowen and Companys 28th Annual Health Care Conference
4. XTENT Announces 2007 Financial Results
5. New study shows extent of harmful human influences on global ecosystems
6. XTENT Announces 2007 Financial Results Conference Call
7. XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe
8. XTENT Announces Third Quarter 2007 Financial Results
9. eDiets.com(R) Announces Q2 2008 Results
10. CPI International Announces Third Quarter 2008 Financial Results
11. MedQuist Announces Changes to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... 2016 , ... Fertility Centers of New England announced today the opening of ... Center provides convenient access to care for patients seeking fertility treatment in Maine. “We ... Comprehensive Care in Portland,” said Fertility Centers of New England President and CEO, Joseph ...
(Date:5/4/2016)... ... 2016 , ... Vasont Systems, a top component content management ... the latest release of Adobe FrameMaker, Release 2015. The integration of the Vasont® ... editing and storing XML. , The VUI creates a smooth continued ...
(Date:5/3/2016)... Minnesota (PRWEB) , ... May 04, 2016 , ... ... more than 40 national and global construction firms representing the Construction Industry Safety ... have joined forces with one purpose: to inspire everyone in the industry to ...
(Date:5/3/2016)... Garden City, NY (PRWEB) , ... May 04, 2016 , ... ... as a 2016-2017 inductee into its VIP Woman of the Year Circle. She ... leading networking organization exclusively for professional women, boasting more than 850,000 members and over ...
(Date:5/3/2016)... CA (PRWEB) , ... May 03, 2016 , ... ... on Denver Business Journal, patients report dissatisfaction with numerous issues related to medical ... personnel, issues with billing, and poor bedside manner from hospital staff. Commenting on ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... , May 4, 2016 ... 154 pages, profiling 09 key companies and supported ... professional and in-depth study on the current state ... overview of the industry including definitions, classifications, applications ... analysis is provided for the international market including ...
(Date:5/3/2016)... , May 4, 2016 ... "Global Cancer Stem Cell Therapy Market Outlook 2020" ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,Recombinant technology has improved ... are expected to be developed in coming years. Many ... techniques. Cancer stem cell therapies are also expected to ...
(Date:5/3/2016)... , May 3, 2016  As a teenager, ... contracted rheumatic fever, which damaged his heart. He continued ... But by June 2013, Shepherd,s heart was giving out ... death. On June 20, 2013, the Mesa, ... Artificial Heart (TAH-t). Like a heart transplant, the SynCardia ...
Breaking Medicine Technology: